+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Predictors of survival and disease-free survival in patients with resected N1 non-small cell lung cancer



Predictors of survival and disease-free survival in patients with resected N1 non-small cell lung cancer



Annals of Thoracic Surgery 84(1): 182



Factors that predict poor survival or increased risk of recurrence for patients with N1 disease may be dependent on tumor characteristics. This study was a retrospective review of a prospective database of consecutive patients who had clinical or pathologic N1 non-small cell lung cancer (NSCLC) who underwent preoperative 2-[18F] fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET) scans and complete resection with thoracic lymphadenectomy. There were 135 patients (88 men). The 5-year disease-free rate was 55%. Kaplan-Meier analysis showed that poor differentiation (p = 0.036), multiple N1 stations (p = 0.010), and the lack of adjuvant chemotherapy (p = 0.039) were all associated with a shorter 5-year disease-free rate. Multivariate disease-free analysis demonstrated that only multiple stations (p = 0.002) were independently associated with recurrence. The overall 5-year survival was 48%. Univariate analysis showed that multiple nodes within one station (p = 0.016), multiple station involvement (p = 0.041), and lack of adjuvant chemotherapy (p = 0.039) and moderate-to-poor tumor differentiation (p = 0.046) were associated with decreased survival. Multivariate analysis found that multiple stations, multiple nodes, and lack of adjuvant chemotherapy were independent predictors of poor survival. Integrated PET-computed tomography (CT) was significantly more sensitive for staging N1 disease than dedicated FDG-PET (p = 0.032). Neoadjuvant chemotherapy given to 48 nonrandomized patients did not seem to impact disease recurrence or overall 5-year survival rates (p = 0.349). Factors that predict a poor outcome in patients with resected N1 NSCLC are the involvement of multiple N1 stations, multiple N1 nodes, and the lack of adjuvant chemotherapy. Integrated PET-CT is more sensitive for detecting N1 disease then dedicated PET. These data may influence preoperative or postoperative therapy, or both.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055113649

Download citation: RISBibTeXText

PMID: 17588408

DOI: 10.1016/j.athoracsur.2007.03.030


Related references

Favorable Disease-free Survival Associated with Programmed Death Ligand 1 Expression in Patients with Surgically Resected Small-cell Lung Cancer. Anticancer Research 36(8): 4329-4336, 2016

Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer. Lung Cancer 128: 152-157, 2019

Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide. Canadian Respiratory Journal 2016: 5405810, 2016

Predictors of post-recurrence survival in patients with non-small-cell lung cancer initially completely resected. Interactive Cardiovascular and Thoracic Surgery 21(1): 14-20, 2015

Interleukin polymorphisms associated with overall survival, disease-free survival, and recurrence in non-small cell lung cancer patients. Molecular Carcinogenesis 54(Suppl. 1): E172, 2015

Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. Journal of Thoracic Oncology 3(4): 365-373, 2008

Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients. Cancer ChemoTherapy and Pharmacology 71(3): 671-680, 2013

P1.08-018 Positive N Stage is a Risk Factor for Survival in Five-Year Disease Free Survivors with Completely Resected Non-Small Cell Lung Cancer. Journal of Thoracic Oncology 12(1): S740-S741, 2017

Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease. Journal of Thoracic and Cardiovascular Surgery 128(1): 130-137, 2004

Prognostic factors in resected stage I non-small cell lung cancer with a diameter of 3 cm or less: visceral pleural invasion did not influence overall and disease-free survival. Journal of Thoracic and Cardiovascular Surgery 134(3): 638-643, 2007

A comparison of the survival and disease-specific survival of surgically resected, node-positive bronchioloalveolar carcinoma to that of non-small cell lung cancer: Implications for adjuvant therapy. Journal of Clinical Oncology 26(15_Suppl): 7536-7536, 2016

PD5-3-4: The impact of multiplicity of metastatic nodal stations on survival in surgically resected non-small cell lung cancer patients: Is N2 disease really different from N1 disease?. Journal of Thoracic Oncology 2(8): S479-S480, 2007

Prophylactic cranial irradiation improved the overall survival of patients with surgically resected small cell lung cancer, but not for stage I disease. Lung Cancer 86(3): 334-338, 2014

Recurrence-free survival and prognostic factors in resected pN2 non-small cell lung cancer. European Journal of Cardio-Thoracic Surgery 22(5): 695-700, 2002

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer. Annals of Thoracic Medicine 10(1): 61-66, 2015